Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsPersonalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challengesPharmacogenetics and anaesthesia: the value of genetic profilingThe genetics of substance dependencePharmacogenetics of OPRM1.DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion.Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes.The application of genomic and molecular data in the treatment of chronic cancer pain.Pharmacogenomic considerations in opioid analgesia.Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitroClinical and genetic factors related to cancer-induced bone pain and bone pain relief.Haplotype block structure of the genomic region of the mu opioid receptor gene.Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)Pharmacogenetics of new analgesics.Individual differences in morphine and butorphanol analgesia: a laboratory pain study.Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca²⁺ channels in humanized mouse sensory neurons.A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents.Relationship of pain and ancestry in African American women.Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapyPain sensitivity and opioid analgesia: a pharmacogenomic twin studyPharmacogenetics of analgesic drugsA non-synonymous single nucleotide polymorphism in an OPRM1 splice variant is associated with fentanyl-induced emesis in women undergoing minor gynaecological surgeryBuprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy.Gender, variation in opioid receptor genes and sensitivity to experimental pain.Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphismPharmacogenetics of chronic pain and its treatment.Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity.Genes and epigenetic processes as prospective pain targetsNature and nurture of human pain.Associations between KCNJ6 (GIRK2) gene polymorphisms and pain-related phenotypes.Zebrafish: a model for the study of addiction geneticsPhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Personalized therapy in pain management: where do we stand?Genetic variability of pain perception and treatment--clinical pharmacological implications.Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring.Recent advances in the understanding of genetic susceptibility to chronic pain and somatic symptoms.Pharmacogenomics of the human µ-opioid receptor.
P2860
Q21284753-90F5DB71-D935-443B-81F4-325D9ADE432EQ24627422-9FD723CE-B10A-4F49-A5D7-8D66A30EDCD8Q26859221-EB24835C-7DB8-4A9E-9EDF-571A64259B56Q27002251-4EBDDDE6-5A53-4BBE-B29F-068F9C303E35Q33568294-302A66CB-2DC0-4CF7-B775-D8898ADCA985Q33688183-F52A25DF-0C31-446F-8F1F-AAE750D025E2Q33802439-BCE7835E-E521-499B-A741-32A04BE3164CQ34207230-0E1EE3F3-C91B-4056-A7F0-D992A0F0E636Q34316700-C8838D55-30BF-48DF-AEF1-69D2ACD99129Q34559598-5FE43594-433D-4B83-B704-61A9C831C699Q34641014-BA4DDF21-8312-4562-8070-A08483B8282EQ34786964-60BD0617-9A9F-4A34-BDDC-AE0C82529E31Q34939590-5CA1F26B-324C-44A7-9F91-26D5156C13D2Q35005640-E214ACF6-6049-476F-8B2D-E9640DFF7B39Q35163746-57E76969-4688-4A13-9D86-E24AB47152FBQ35464108-0E959A17-DF8D-4E58-A7AE-0E8B35CBEDBAQ35484325-C7BD8ED4-56F9-4D7B-927E-03A299FD5B3FQ35528692-A9BCBF7C-BEFD-4D8D-82FC-983A383D30F9Q35607376-A8EE2846-6FAE-4744-8F47-EB0DBDCE3623Q35654120-DDCA9C51-F956-43FD-9785-13BBFA036D30Q36040669-DE3B1015-329D-4598-B29C-5B877DAC0401Q36110592-FCC4110E-B5A3-4D47-B812-DEE64B437AF4Q36380880-F2201831-C688-4CD3-AFD9-17CFF3DC4288Q36394429-397E4C5F-1502-41A2-9795-8DA34186DAEBQ36773493-FB2CDB84-B796-4AA4-9C21-7E3F9A857103Q36794010-F2C7C817-CD75-48FD-B053-AC21E46F28DDQ36821195-67F0DB61-2EEF-4D65-8B49-A1C824C8931BQ36844846-1392F223-8D67-44E7-9C93-C6723E9522C7Q36900075-9F1B261A-9E56-403E-83E1-9D39608D8684Q36932009-16EC77B7-D738-4F84-A8FD-28D38E89E8D4Q36998001-9842D652-A1B8-412F-9C51-D688C57D61E3Q37287580-478DDE72-FEA8-4EF4-8C08-8F4509D8C7F6Q37353507-1C4CC142-DA7D-48F7-8773-75360A810F21Q37387341-F48B19B3-76A3-4ECA-86B9-AABACDF75204Q37491434-49B0E496-D17C-4F68-9842-204A81B0E5B8Q37760955-297142AA-F290-438B-B09E-9DB2227A058AQ37846139-9EB8AA22-C8BE-4657-9B96-37BBD2A1EF1AQ37876422-2DDC6370-A33C-4375-A1E6-D3D9569E7B11Q37923857-8AF4990C-4327-40CF-AEFC-7BD12CC04356Q37932516-9EB84B25-4C54-4F70-B403-2E26ED8F663E
P2860
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@en
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@nl
type
label
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@en
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@nl
prefLabel
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@en
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@nl
P1433
P1476
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
@en
P2093
Carmen Walter
P304
P356
10.1016/J.PAIN.2009.07.013
P407
P50
P577
2009-08-14T00:00:00Z